Abstract: The invention relates to filter dedicated to protect eye cone cells and method associated. The eye cone cells protecting filter is intended to be applied to a transparent surface and to filter incident light for preventing eye cone cells of a user, from damages due to illumination at physiological light levels on the eye of said user, and having spectral characteristics to i) filter light wavelengths between 405 and 465 nanometers, and ii) transmit a filtered light reaching the eye cone cells and having a harmfulness on said eye cone cells under a predefined maximum threshold.

Abstract: The present invention relates to the combination of a nucleic acid encoding a short isoform of rod-derived cone viability factor (RdCVF), a nucleic acid encoding a long isoform of rod-derived cone viability factor (RdCVFL) and a nucleic acid encoding a G protein-activated Inward Rectifier potassium channel 2 (GIRK2), expressed through one, two or three viral vectors, said vectors may be within a single pharmaceutical composition or within several different pharmaceutical compositions (two or three). It also deals with the treatment of a retinal degenerative disease, in particular the retinitis pigmentosa, with said viral vectors or pharmaceutical compositions.

Abstract: Disclosed are, among other methods, methods for reactivating retinal ganglion cells in mammals by administering an effective amount of channelrhodopsins (such as ChrimsonR), or an effective amount of such channelrhodopsins (such as ChrimsonR) fused to a fluorescent protein. In the form of protein or nucleic acids, and compositions thereof. The methods may include a light stimuli level inducing RGCs response that is below radiation safety limit. The methods may include delivery by an adenoassociated virus vector. The methods may include use of a CAG promoter. The methods may result in a long term expression of an effective amount of the channelrhodopsins (such as ChrimsonR protein).

Abstract: The invention relates to filter dedicated to protect eye cone cells and method associated. The eye cone cells protecting filter is intended to be applied to a transparent surface and to filter incident light for preventing eye cone cells of a user, from damages due to illumination at physiological light levels on the eye of said user, and having spectral characteristics to i) filter light wavelengths between 405 and 465 nanometers, and ii) transmit a filtered light reaching the eye cone cells and having a harmfulness on said eye cone cells under a predefined maximum threshold.

Abstract: Disclosed are, among other methods, methods for reactivating retinal ganglion cells in mammals by administering an effective amount of channelrhodopsins (such as ChrimsonR), or an effective amount of such channelrhodopsins (such as ChrimsonR) fused to a fluorescent protein, in the form of protein or nucleic acids, and compositions thereof. The methods may include a light stimuli level inducing RGCs response that is below radiation safety limit. The methods may include delivery by an adenoassociated virus vector. The methods may include use of a CAG promoter. The methods may result in a long term expression of an effective amount of the channelrhodopsins (such as ChrimsonR protein).

Abstract: An input signal (f) representative of a scene to be viewed comprises, for each pixel of a matrix of pixels, an event-based asynchronous-signal sequence obtained as a function of variations of light relating to the pixel in the scene. This input signal is transformed spatially within the matrix of pixels and temporally along the signal sequences to generate respective control signals (S) for pixel zones of a device for aiding vision (20).

Abstract: The invention relates to an implant which includes, in order to electrically stimulate a nerve structure, in particular the retina, an electrically insulating substrate (1), a array of recesses (2) formed in an upper surface of the substrate, stimulation electrodes (3) arranged at the bottom of the recesses, and an electrically conductive layer forming a ground plane (4) at the upper portion of the recesses. The sizes of the recesses and of the electrodes of the implant are such that the spatial selectivity of the stimulation current applied to the nerve structure is maximized.

Abstract: The present invention relates to a non human animal model for increased retinal vascular permeability wherein said increased retinal vascular permeability is induced by inhibiting in Müller cells of said animal the expression of a gene encoding for Dp71 or a dystrophin associated protein (DAP). Furthermore, the present invention relates to methods and compositions for the treatment of a disease associated with an increased retinal vascular permeability in a subject in need thereof.

Abstract: An input signal (f) representative of a scene to be viewed comprises, for each pixel of a matrix of pixels, an event-based asynchronous-signal sequence obtained as a function of variations of light relating to the pixel in the scene. This input signal is transformed spatially within the matrix of pixels and temporally along the signal sequences to generate respective control signals (S) for pixel zones of a device for aiding vision (20).

Abstract: The invention relates to an implant which includes, in order to electrically stimulate a nerve structure, in particular the retina, an electrically insulating substrate (1), a array of recesses (2) formed in an upper surface of the substrate, stimulation electrodes (3) arranged at the bottom of the recesses, and an electrically conductive layer forming a ground plane (4) at the upper portion of the recesses.

Abstract: The present invention relates to a non human animal model for increased retinal vascular permeability wherein said increased retinal vascular permeability is induced by inhibiting in Müller cells of said animal the expression of a gene encoding for Dp71 or a dystrophin associated protein (DAP). Furthermore, the present invention relates to methods and compositions for the treatment of a disease associated with an increased retinal vascular permeability in a subject in need thereof.

Abstract: The present invention pertains to pharmaceutical compositions including, as the active ingredients, a combination of vigabatrin and of at least one glutamate receptor activating substance.

Abstract: Pharmaceutical compositions including, as the active ingredients, a combination of vigabatrin and of at least one substance having anti-ischemic effect, are disclosed.

Abstract: Pharmaceutical compositions for inhibiting, preventing or treating unwanted angiogenesis/neovascularization, including that of ocular tissues, contain agents that inhibit VEGF in combination with a second therapy, e.g., that elicited by serine proteases/thrombolytic compounds.

Abstract: Disclosed are methods and compositions for early diagnosis, monitoring and treatment of retinal dystrophy, age-related macular degeneration, Bardet-Biedel syndrome, Bassen-kornzweig syndrome, best disease, choroidema, gyrate atrophy, congenital amourosis, refsun syndrome, stargardt disease and Usher syndrome. In particular, the invention relates to a protein, termed “Rdcvf1,” that is differentially transcribed and expressed in subjects suffering from retinal dystrophies and the like, such as retinal dystrophy and age-related macular degeneration compared with non-sufferers, antibodies which recognize this protein, and methods for diagnosing such conditions.

Abstract: The invention concerns the use of a calcium channel blocker compound and/or cyclic GMP-dependent channels, namely diltiazem, for treating retinal pathologies, and more particularly retinal diseases caused by degeneration of visual receptors, in a human or animal.